Edition:
United Kingdom

Valeant acquires Canadian rights for Contrave in treatment of obesity


Tuesday, 30 Aug 2016 

Valeant Pharmaceuticals International Inc : Valeant acquires the Canadian rights for Contrave® in the treatment of obesity . Valeant expects to file with health Canada for regulatory approval by January 2017 . Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses . Says Orexigen and Valeant anticipate launching Mysimba in 11 countries in Q4 of 2016 .Orexigen and Valeant anticipate launching Mysimba in 2 countries, in addition to 11 countries, in Q1 of 2017.